Yu Zheng1, Angela L Tyner. 1. Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL 60607, USA.
Abstract
BACKGROUND: Protein tyrosine kinase 6 (PTK6) is an intracellular tyrosine kinase that is distantly related to SRC family kinases. PTK6 is nuclear in normal prostate epithelia, but nuclear localization is lost in prostate tumours. Increased expression of PTK6 is detected in human prostate cancer, especially at metastatic stages, and in other types of cancers, including breast, colon, head and neck cancers, and serous carcinoma of the ovary. MATERIALS AND METHODS: Potential novel substrates of PTK6 identified by mass spectrometry were validated in vitro. The significance of PTK6-induced phosphorylation of these substrates was addressed using human prostate cell lines by knockdown of endogenous PTK6 or overexpression of targeted PTK6 to different intracellular compartments. RESULTS: We identified AKT, p130CAS and focal adhesion kinase (FAK) as novel PTK6 substrates and demonstrated their roles in promoting cell proliferation, migration and resistance to anoikis. In prostate cancer cells, active PTK6 is primarily associated with membrane compartments, although the majority of total PTK6 is localized within the cytoplasm. Ectopic expression of membrane-targeted PTK6 transforms immortalized fibroblasts. Knockdown of endogenous cytoplasmic PTK6 in PC3 prostate cancer cells impairs proliferation, migration and anoikis resistance. However, re-introduction of PTK6 into the nucleus significantly decreases cell proliferation, suggesting context-specific functions for nuclear PTK6. CONCLUSIONS: In human prostate cancer, elevated PTK6 expression, translocation of PTK6 from the nucleus to the cytoplasm and its activation at the plasma membrane contribute to increased phosphorylation and activation of its substrates such as AKT, p130CAS and FAK, thereby promoting prostate cancer progression.
BACKGROUND:Protein tyrosine kinase 6 (PTK6) is an intracellular tyrosine kinase that is distantly related to SRC family kinases. PTK6 is nuclear in normal prostate epithelia, but nuclear localization is lost in prostate tumours. Increased expression of PTK6 is detected in humanprostate cancer, especially at metastatic stages, and in other types of cancers, including breast, colon, head and neck cancers, and serous carcinoma of the ovary. MATERIALS AND METHODS: Potential novel substrates of PTK6 identified by mass spectrometry were validated in vitro. The significance of PTK6-induced phosphorylation of these substrates was addressed using human prostate cell lines by knockdown of endogenous PTK6 or overexpression of targeted PTK6 to different intracellular compartments. RESULTS: We identified AKT, p130CAS and focal adhesion kinase (FAK) as novel PTK6 substrates and demonstrated their roles in promoting cell proliferation, migration and resistance to anoikis. In prostate cancer cells, active PTK6 is primarily associated with membrane compartments, although the majority of total PTK6 is localized within the cytoplasm. Ectopic expression of membrane-targeted PTK6 transforms immortalized fibroblasts. Knockdown of endogenous cytoplasmic PTK6 in PC3prostate cancer cells impairs proliferation, migration and anoikis resistance. However, re-introduction of PTK6 into the nucleus significantly decreases cell proliferation, suggesting context-specific functions for nuclear PTK6. CONCLUSIONS: In humanprostate cancer, elevated PTK6 expression, translocation of PTK6 from the nucleus to the cytoplasm and its activation at the plasma membrane contribute to increased phosphorylation and activation of its substrates such as AKT, p130CAS and FAK, thereby promoting prostate cancer progression.
Authors: Anne J Ridley; Martin A Schwartz; Keith Burridge; Richard A Firtel; Mark H Ginsberg; Gary Borisy; J Thomas Parsons; Alan Rick Horwitz Journal: Science Date: 2003-12-05 Impact factor: 47.728
Authors: Egle Avizienyte; Anne W Wyke; Robert J Jones; Gordon W McLean; M Andrew Westhoff; Valerie G Brunton; Margaret C Frame Journal: Nat Cell Biol Date: 2002-08 Impact factor: 28.824
Authors: Stephanie Ma; Jessie Y J Bao; Pak Shing Kwan; Yuen Piu Chan; Carol M Tong; Li Fu; Na Zhang; Amy H Y Tong; Yan-Ru Qin; Sai Wah Tsao; Kwok Wah Chan; Si Lok; Xin-Yuan Guan Journal: Gastroenterology Date: 2012-06-13 Impact factor: 22.682
Authors: Tao Xie; Giovanni D' Ario; John R Lamb; Eric Martin; Kai Wang; Sabine Tejpar; Mauro Delorenzi; Fred T Bosman; Arnaud D Roth; Pu Yan; Stephanie Bougel; Antonio Fabio Di Narzo; Vlad Popovici; Eva Budinská; Mao Mao; Scott L Weinrich; Paul A Rejto; J Graeme Hodgson Journal: PLoS One Date: 2012-07-31 Impact factor: 3.240
Authors: Darren J Wozniak; Ben Hitchinson; Milica B Gilic; Wenjun Bie; Vadim Gaponenko; Angela L Tyner Journal: Mol Cancer Ther Date: 2019-03-29 Impact factor: 6.261
Authors: Priya S Mathur; Jessica J Gierut; Grace Guzman; Hui Xie; Rosa M Xicola; Xavier Llor; Michael I Chastkofsky; Ansu O Perekatt; Angela L Tyner Journal: Mol Cancer Res Date: 2016-03-16 Impact factor: 5.852
Authors: Yu Zheng; Zebin Wang; Wenjun Bie; Patrick M Brauer; Bethany E Perez White; Jing Li; Veronique Nogueira; Pradip Raychaudhuri; Nissim Hay; Debra A Tonetti; Virgilia Macias; André Kajdacsy-Balla; Angela L Tyner Journal: Cancer Res Date: 2013-07-15 Impact factor: 12.701
Authors: Xiaohong Chen; Bo Song; Yuanlong Lin; Lijun Cao; Shiyan Feng; Lin Zhang; Fuxiang Wang Journal: Am J Transl Res Date: 2016-10-15 Impact factor: 4.060
Authors: Amy R Dwyer; Carlos Perez Kerkvliet; Raisa I Krutilina; Hilaire C Playa; Tiffany N Seagroves; Carol A Lange; Deanna N Parke; Warner A Thomas; Branden A Smeester; Branden S Moriarity Journal: Mol Cancer Res Date: 2020-11-10 Impact factor: 6.333
Authors: Michael I Chastkofsky; Wenjun Bie; Susan M Ball-Kell; Yu-Ying He; Angela L Tyner Journal: J Invest Dermatol Date: 2015-04-30 Impact factor: 8.551